CoChat

Role of aramchol in steatohepatitis and fibrosis in mice

Open access
Iruarrizaga‐Lejarreta, Marta, Varela‐Rey, Marta, Fernández‐Ramos, David, Martínez‐Arranz, Ibon, Delgado, Teresa C, Simon, Jorge, Gutiérrez‐de Juan, Virginia, delaCruz‐Villar, Laura, Azkargorta, Mikel, Lavin, José L., Mayo, Rebeca, Van Liempd, Sebastiaan M., Aurrekoetxea, Igor, Buqué, Xabier, Delle Cave, Donatella, Peña, Arantza, Rodríguez‐Cuesta, Juan, Aransay, Ana M., Elortza, Felix, Falcón‐Pérez, Juan M., Aspichueta, Patricia, Hayardeny, Liat, Noureddin, Mazen, Sanyal, Arun J., Alonso, Cristina, Anguita, Juan, Martínez‐Chantar, María Luz, Lu, Shelly C., Mato, José M. · 2017 · Hepatology Communications
Cited by 113

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD) that sets the stage for further liver damage. The mechanism for the progression of NASH involves multiple parallel hits, including oxidative stress, mitochondrial dysfunction, inflammation, and others. Manipulation of any of these pathways may be an approach to prevent NASH development and progression. Arachidyl‐amido cholanoic acid (Aramchol) is presently in a phase IIb NASH study. The aim of the present study was to investigate Aramchol's mechanism of action and its effect on fibrosis using the methionine‐ and choline‐deficient (MCD) diet model of NASH. We collected liver and serum from mice fed an MCD diet containing 0.1% methionine (0.1MCD) for 4 weeks; these mice developed steatohepatitis and fibrosis. We also collected liver and serum from mice receiving a control diet, and metabolomes and proteomes were determined for both groups. The 0.1MCD‐fed mice were given Aramchol (5 mg/kg/day for the last 2 weeks), and liver samples were analyzed histologically. Aramchol administration reduced features of steatohepatitis and fibrosis in 0.1MCD‐fed mice. Aramchol down‐regulated stearoyl‐coenyzme A desaturase 1, a key enzyme involved in triglyceride biosynthesis and the loss of which enhances fatty acid β‐oxidation. Aramchol increased the flux through the transsulfuration pathway, leading to a rise in glutathione (GSH) and the GSH/oxidized GSH ratio, the main cellular antioxidant that maintains intracellular redox status. Comparison of the serum metabolomic pattern between 0.1MCD‐fed mice and patients with NAFLD showed a substantial overlap. Conclusion: Aramchol treatment improved steatohepatitis and fibrosis by 1) decreasing stearoyl‐coenyzme A desaturase 1 and 2) increasing the flux through the transsulfuration pathway maintaining cellular redox homeostasis. We also demonstrated that the 0.1MCD model resembles the metabolic phenotype observed in about 50% of patients with NAFLD, which supports the potential use of Aramchol in NASH treatment. (Hepatology Communications 2017;1:911–927)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep4.1107

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 113

Metadata

Authors
Iruarrizaga‐Lejarreta, M., Varela‐Rey, M., Fernández‐Ramos, D., Martínez‐Arranz, I., Delgado, T. C., Simon, J., Gutiérrez‐de Juan, V., delaCruz‐Villar, L., Azkargorta, M., Lavin, J. L., Mayo, R., Van Liempd, S. M., Aurrekoetxea, I., Buqué, X., Delle Cave, D., Peña, A., Rodríguez‐Cuesta, J., Aransay, A. M., Elortza, F., Falcón‐Pérez, J. M., Aspichueta, P., Hayardeny, L., Noureddin, M., Sanyal, A. J., Alonso, C., Anguita, J., Martínez‐Chantar, M. L., Lu, S. C., & Mato, J. M.
Venue
Hepatology Communications
Published
2017-10-04
Volume
1
Issue
9
Pages
911-927
ISSN
2471-254X (ISSN-L)
OpenAlex
W2761787658
Cited by
113
References
10
FWCI
6.31
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.